Online Platforms for Alzheimer's Disease Information Delivery
(eSMARTER Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of two methods for delivering Alzheimer's test results. One group will use an online platform, the eHealth Platform, featuring a web portal and chatbot. The other group will have videoconference appointments with healthcare providers, known as the Videoconference Telehealth Platform. The trial aims to determine if the online approach matches the effectiveness of professional consultations. Individuals with internet access who can read and speak English and are comfortable learning about Alzheimer's-related health information may be suitable participants. As an unphased trial, this study allows participants to contribute to innovative approaches in healthcare communication.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What prior data suggests that these platforms are safe for delivering Alzheimer's-related information?
Research has shown that digital health tools, such as the eHealth platform, are generally safe and helpful for those learning about Alzheimer’s. Studies have found that these platforms simplify access to information and health management without major issues. For instance, digital health technologies assist with screening and diagnosis and allow individuals to access their health information at their own pace.
No specific evidence indicates that using these platforms is unsafe. Instead, they are often praised for enabling flexible learning and discussion about health concerns. This suggests that the eHealth platform is likely well-tolerated, based on the use of similar tools in other settings.12345Why are researchers excited about this trial?
Researchers are excited about these platforms for delivering Alzheimer's information because they offer innovative ways to communicate test results and healthcare guidance. The eHealth platform is unique because it combines a self-directed web portal and a chatbot, allowing users to access information flexibly and even schedule virtual appointments, which can enhance patient engagement and autonomy. The videoconference telehealth platform, on the other hand, provides real-time interaction with healthcare providers remotely, making it more convenient for patients who may have mobility issues. Both platforms aim to improve accessibility and personalize care, potentially leading to better patient outcomes compared to traditional, in-person consultations.
What evidence suggests that this trial's methods could be effective for delivering Alzheimer's information?
Research has shown that digital health tools can benefit people with Alzheimer's disease. Studies have found that these tools assist with early detection, diagnosis, and ongoing monitoring. Specifically, online health platforms can enhance mental and social functioning and improve caregiving. They also facilitate communication and information sharing between patients and healthcare providers.
In this trial, participants will be randomized to receive their Alzheimer's-related test results through one of two platforms. The eHealth platform, which includes a self-directed web portal and chatbot, allows participants to switch between these tools or schedule a virtual appointment with a healthcare provider. Alternatively, the videoconference telehealth platform provides remote visits with a healthcare provider for personalized advice and support. Both methods aim to make health information easier to deliver and understand.23467Who Is on the Research Team?
Jessica Langbaum, PhD
Principal Investigator
Banner Alzheimer's Institute
Are You a Good Fit for This Trial?
This trial is for individuals who can follow the study's procedures, are fluent in English, willing to have their blood drawn for future testing, and have internet access with a device. They must understand the consent form content to participate.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-disclosure Education
Participants use eHealth platforms (ADWebPortal or ADChatbot) for pre-disclosure education
Disclosure
Participants receive Alzheimer's gene and biomarker results via eHealth platform or telehealth videoconference
Follow-up
Participants are monitored for psychological and cognitive impacts post-disclosure
What Are the Treatments Tested in This Trial?
Interventions
- eHealth Platform
- Videoconference Telehealth Platform
Find a Clinic Near You
Who Is Running the Clinical Trial?
Banner Health
Lead Sponsor
National Institute on Aging (NIA)
Collaborator
University of Pennsylvania
Collaborator